Comparison between population with severe (ZZ) and intermediate (MZ) alpha1-antitrypsin deficiency and established COPD
D. Piloni (Pavia, Italy), M. Mennitti (Pavia, Italy), L. Corda (Brescia, Italy), P. Baderna (Aosta, Italy), S. Ottaviani (Pavia, Italy), A. Balderacchi (Pavia, Italy), V. Barzon (Pavia, Italy), C. Tirelli (Pavia, Italy), F. Albicini (Pavia, Italy), F. Spreafico (Brescia, Italy), L. Saderi (Sassari, Italy), G. Sotgiu (Sassari, Italy), I. Ferrarotti (Pavia, Italy), A. Corsico (Pavia, Italy)
Source: International Congress 2019 – Advances in clinical management of COPD
Session: Advances in clinical management of COPD
Session type: Poster Discussion
Number: 3894
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Piloni (Pavia, Italy), M. Mennitti (Pavia, Italy), L. Corda (Brescia, Italy), P. Baderna (Aosta, Italy), S. Ottaviani (Pavia, Italy), A. Balderacchi (Pavia, Italy), V. Barzon (Pavia, Italy), C. Tirelli (Pavia, Italy), F. Albicini (Pavia, Italy), F. Spreafico (Brescia, Italy), L. Saderi (Sassari, Italy), G. Sotgiu (Sassari, Italy), I. Ferrarotti (Pavia, Italy), A. Corsico (Pavia, Italy). Comparison between population with severe (ZZ) and intermediate (MZ) alpha1-antitrypsin deficiency and established COPD. 3894
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Characterization of a population of alpha1 -antitrypsin deficient (A1 ATD) patients Source: Annual Congress 2008 - COPD Year: 2008
Prevalence of alpha-1-antitrypsin deficiency (A1AD) in patients with COPD. Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021
Tracing down the evolutionary history of Q0Ourém , a rare allele associated with severe alpha-1-antitrypsin deficiency (AATD) Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009
Mortality in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) Source: Eur Respir J 2006; 28: Suppl. 50, 144s Year: 2006
Risk of cancer in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) compared with the Swedish general population Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement? Year: 2020
Higher than expected prevalence of alpha-1-antitrypsin deficiency (AATD) may not necessarily impact on airflow, gas exchange or acute exacerbation rate (AER) Source: Annual Congress 2012 - Prevalences and characterstics of obstructive airway disease Year: 2012
Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency Source: Annual Congress 2010 - COPD: phenotyping and monitoring Year: 2010
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013
Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD). Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases Year: 2021
Investigating change in the COPD assessment test (CAT) within α-1 antitrypsin deficiency (A1ATD) Source: Annual Congress 2011 - Phenotyping and monitoring of airway diseases Year: 2011
Frequency of α-1 antitrypsin deficiency (AATD) in a population screening in an high risk area (Val Trompia, Italy) Source: Eur Respir J 2006; 28: Suppl. 50, 453s Year: 2006
Incidence of alpha-1-antitrypsin (α1-AT) deficiency in patients with COPD in Poland, preliminary report Source: Eur Respir J 2005; 26: Suppl. 49, 440s Year: 2005
COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level Source: Annual Congress 2012 - COPD exacerbation Year: 2012
Role of genetic factors in COPD (alpha-1-antitrypsin deficiency and other factors) Source: Annual Congress 2005 - PG13 - COPD: genetic and environmental factors, epidemiology, socio-economic impact and preventative measures Year: 2005
Serum surfactant protein D (SPD) as a specific marker for COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
α-1 antitrypsin PI MZ heterozygotes have reduced lung function in two large cohorts Source: Annual Congress 2009 - Environmental and genetic risk factors for asthma and COPD Year: 2009
Health status changes in alpha-1-antitrypsin deficiency (PiZ phenotype) over 3 years Source: Annual Congress 2003 - Alpha-1 antitrypsin deficiency and COPD Year: 2003
Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
Prevalence of alpha-1 antitrypsin deficiency (AATD) and frequencies of alleles PI*S and PI*Z in patients with COPD in Brazil Source: Annual Congress 2013 –Assessing the prevalence of COPD in the general population Year: 2013